Application of Optical Coherence Tomography in the Detection and Classification of Cognitive Decline

Moon J Lee, Alison G Abraham, Bonnielin K Swenor, A Richey Sharrett, Pradeep Y Ramulu

ABSTRACT

Aim: This review aims to critically analyze the current literature on the relationship of optical coherence tomography (OCT) measures to cognition and dementia.

Background: Optical coherence tomography, a noninvasive method of imaging neuroretinal layers, and OCT angiography, a highly precise method of examining retinal vasculature, have widely been used to aid in the diagnosis and monitoring of a variety of ocular diseases. There is now an increasing body of evidence relating the structural and microvascular changes of the retina to cognitive impairment.

Review results: In general, several studies have found decreased retinal nerve fiber layer (RNFL) thickness in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) and an association between RNFL thickness and continuous measures of cognitive ability, though findings were inconsistent across studies. In many studies, associations were found for specific regions of the RNFL but not with overall thickness. Studies linking OCT measures to non-Alzheimer’s dementia were lacking, and limited work has been done on persons with past cognitive decline but who remain cognitively normal (the ideal stage at which to target treatment). Common limitations of prior studies include a failure to account for intracocular pressure (IOP) and axial length.

Conclusion: Current research suggests a potential association between retinal findings observed on OCT and cognitive impairment. Methodologically robust research accounting for important covariates and looking at changes in OCT and/or cognition is needed to better characterize the association between OCT and cognitive ability.

Clinical significance: Further research is warranted to determine whether OCT findings can help identify the etiology of cognitive decline and/or serve as objective markers of AD. If this is the case, OCT may also help identify the presence of disease processes in cognitively normal individuals.

Keywords: Alzheimer’s disease, Cognitive impairment, Dementia, Literature review, Optical coherence tomography (OCT), Retinal nerve fiber layer.

How to cite this article: Lee MJ, Abraham AG, Swenor BK, Sharrett AR, Ramulu PY. Application of Optical Coherence Tomography in the Detection and Classification of Cognitive Decline. J Curr Glaucoma Pract 2018;12(1):10-18.

Source of support: Nil
Conflict of interest: None

BACKGROUND

Introduction

In 2015, the global burden of dementia was an estimated 46.8 million, a figure, that is expected to double by 2035.1 The disease process underlying dementia causes memory loss and cognitive decline in the aging population. The most common clinical dementia diagnosis is AD followed by vascular dementia (VaD). An increasing body of literature suggests that OCT may be used in patients with cognitive impairment to identify structural thinning of specific neuroretinal layers as a surrogate for neurodegeneration in the brain. While past studies have focused on structural OCT measures, recent advances allow OCT machines to also acquire a retinal angiogram through a technique known as OCT angiography, which detects submillimeter regions of nonperfusion that may be analogous to the microinfarcts seen in the autopsied brains of patients with either vascular or mixed dementia. The detection of structural and vascular changes using OCT may help address the challenge of establishing the etiology of dementia. Here, we review the literature associating structural retinal and retinovascular findings with cognitive impairment and discuss the clinical implications.

Determining the Etiology and Future Course of Cognitive Impairment

Dementia may refer to any of a number of conditions including AD, VaD, as well as dementia with Lewy bodies (LBD), Parkinson’s disease dementia, or frontotemporal dementia (FTD). Distinguishing between these causes of dementia is often challenging due to mixed pathology, lack of noninvasive biomarkers of disease, heterogeneous phenotypes, and changing diagnostic criteria.1,2 The use
of OCT offers the possibility that OCT-defined retinal parameters may implicate distinct etiology of cognitive impairment and enhance our understanding of the underlying mechanisms at play. Specifically, the retinal changes associated with distinct dementia profiles may help differentiate between the various etiologies of cognitive decline and aid in identifying individuals likely to develop more rapid cognitive decline allowing for earlier therapeutic intervention.

Previous studies have shown high misdiagnosis rates of dementia type, with inconsistencies in clinical and neuropathological diagnosis, and VaD most often misdiagnosed as AD. Establishing a correct etiology is of importance for both prevention and treatment as the majority of therapeutic interventions currently in development are targeted toward a specific etiologic type of dementia. The gold standard for determining the etiology of cognitive impairment is neuropathology completed at autopsy. However, etiologic distinctions facilitating proper treatment must be made clinically. Additionally, a proper understanding of etiology helps predict the course of disease, including future mortality rates and rates of cognitive decline. If certain retinal findings are associated with specific etiologies, OCT may help improve the accuracy of etiologic dementia diagnosis, with clinical implications for cost as well as the management and treatment of disease. If this is the case, it may provide similar information as cerebrospinal biomarkers without the invasiveness of a spinal tap and more specific or augmentative information than cognitive tests.

It is particularly difficult to determine etiology early on in dementia processes, especially in persons who may be cognitively normal but have declined from their baseline. As a result, there have been significant efforts to identify biomarkers of AD which may identify persons likely to develop the disease, before significant cognitive deficits have occurred. In diagnoses of mild cognitive impairment (MCI), etiology is not a significant consideration and the diagnostic stability of MCI is even lower than in dementia, as the full-range clinical manifestations specific to the underlying cause of cognitive decline may not yet be apparent. This presents a clinically important challenge, as therapeutics aimed at slowing the neurodegenerative process in specific forms of dementia likely need to be administered early in the disease course for maximal efficacy. If OCT can be shown to help identify the cause of cognitive decline and predict which patients are likely to develop future cognitive impairment, then it may have significant clinical value.

Biomarkers of AD Pathologic Processes

One study that demonstrated the possibility of finding biomarkers for specific forms of cognitive impairment is the BIOCARD study. The study began in 1995 and aimed to identify novel biomarkers predicting early cognitive declines among individuals with normal cognition at baseline. They found that high baseline levels of cerebrospinal fluid (CSF) t-tau and/or p-tau combined with low baseline levels of CSF Aβ-42 were associated with decline in cognition among individuals who were cognitively normal at baseline. These CSF markers were then used to classify preclinical Alzheimer’s stages 0, 1, and 2 those with suspected non-Alzheimer’s pathology. Preclinical disease stage 2 (defined by low CSF Aβ-42 and high CSF t-tau or p-tau) was associated with more rapid decline in a cognitive composite score than those in the other two categories. This study demonstrates the potential to use biomarkers to identify individuals at higher risk of cognitive decline, offering more opportunity for early therapeutic intervention. Despite this progress, however, there still exists a clear need to identify early disease makers that can be obtained through less invasive (and less costly) means.

Retinal Changes and Cognitive Decline—Biological Plausibility

The biologic plausibility of the association between retinal pathology and brain pathology is based on shared embryology, anatomy, immunologic responses, disease pathology, and molecular findings across the retina and brain. During embryological development, both the retina and optic nerve extend from the central nervous system (CNS) developing from the diencephalon. Thus, the eye and brain microvasculatures share common physiology and susceptibility, while the blood–ocular barrier closely resembles the structure and properties of the blood–brain barrier. Shared properties across these two barriers include autoregulation, low-flow, and high-oxygen extraction. Hence, shared embryology suggests that the retina and CNS may be susceptible to the same disease processes. In addition, there are structural similarities between retinal ganglion cells (RGCs) and CNS neurons as well as the optic nerve fiber tract and other fiber tracts in the CNS. The RGCs also undergo the same neurodegenerative processes affecting directly injured neurons, resulting in degeneration of axons, glial scar formation, and loss of myelin. Following injury to the optic nerve, biochemical and metabolic changes create an environment that leads to secondary neurodegenerative processes in surrounding neurons. These responses to neuronal injury of the optic nerve are reflective of the secondary neurodegenerative changes that occur in the brain and spinal cord.

Specific structural pathologic changes identified in CNS disorders have also been suggested to occur in retinal
disease. Common pathogenic processes have been identified in AD, glaucoma, and age-related macular degeneration. These include reactive gliosis, inflammation, and oxidative and metabolic stress leading to neuronal death. Additional pathologic similarities in glaucoma and AD include axonal atrophy, deficits in axonal transport, and transsynaptic degeneration in the brain. At the molecular level, immunologic molecules and cytokines present in the CNS have also been identified in immune responses in the eye. Several of the aforementioned commonalities in the brain, spinal cord, and retina have been used to explain the retinal changes associated with AD, which include structural changes of the retinal microvasculature, structural changes in the optic nerve head (ONH), thinning of the RNFL, and, debatably, the presence of AD-associated proteins in the retina.

Findings from autopsy specimens support the presence of different mechanisms underlying the various dementia entities and raise the possibility that OCT measures examining retinal features may be capable of distinguishing persons with these varying cerebral disease mechanisms in vivo. Neuropathological changes reported in AD include amyloid plaques, neurofibrillary tangles, glial responses, and neuronal and synaptic loss. In addition to these molecular findings, AD has also been associated with changes in brain volume of the frontal subcortical region with subsequent involvement of temporoparietal cortical structures. Such changes in brain volume may also be reflected by eye neural volumes (i.e., RNFL thickness) in neurological structures, as demonstrated in other neurologic disease processes. Vascular disease also plays a substantial role in cognitive decline; both VaD and common mixed pathologies result to varying degrees from vascular disease, and similar vascular pathology has been observed in the retina. The vascular defects most strongly associated with cognitive impairment are submillimeter infarcts which are not radiographically visible and, up until now, have only been detectable at autopsy. Optical coherence tomography angiography, which can detect such microvascular changes in the retina, offers a potential way to measure the vascular disease processes occurring in a closely related vascular bed. Thus, OCT, as a single modality, offers the possibility of measuring several factors (i.e., thickness of various retinal layers, vascular density within various beds) that may help identify the reasons for dementia. If so, OCT findings might serve as biomarkers of the specific disease processes underlying cognitive impairment.

**Retinal Photography: Early Evidence of Retinal Changes in Cognitive Decline**

Even before sophisticated retinal measures could be acquired using OCT, early studies utilizing retinal photography suggested that ganglion cell (GC)/optic nerve damage could mark cognitive impairment. Tsai et al evaluated differences in the RNFL, disk pallor, cup-to-disk ratio, cup volume, and rim area in AD vs healthy controls and found a potential for using these parameters to monitor the progression of AD. They found that higher pallor, increased cup-to-disk ratio and cup volume, and decreased disk rim area all correlated significantly with higher Alzheimer’s Disease Assessment Scale (ADAS) scores, raising the possibility that AD processes were occurring concurrently in the eye.

The Atherosclerosis Risk in Communities (ARIC) study investigated the association between retinal vascular changes and cognitive decline. Study visits occurred every 3 years between 1987 and 1998, and tests included retinal photographs and cognitive function assessment. In 2002, the ARIC study reported that retinopathy was independently associated with lower cognitive function in middle-aged individuals without a history of stroke. The ARIC study also found that retinopathy was associated with cerebral atrophy noted by ventricular enlargement on magnetic resonance imaging. Following the ARIC baseline study, a subset of participants were then followed over a period of 14 years. This study found that retinal microvascular changes on retinal photographs were associated with cognitive decline, specifically declines in executive function and psychomotor speed, a finding that persisted even when diabetics were excluded from the analysis. These early longitudinal studies suggest the potential for use of OCT angiography to evaluate retinal microvascular changes as a possible predictor of cognitive decline.

**Precedent for use of OCT in Monitoring Disease**

Optical coherence tomography has been used to image and measure the retina, RNFL, macula, optic nerve, and the anterior chamber. It is a noninvasive, high-resolution imaging technique that provides cross-sectional images of the retina and is increasingly being used to aid in the diagnoses and monitoring of a variety of diseases not limited to the eye, including neurologic disease. The use of OCT in multiple sclerosis (MS) offers a strong precedent for using OCT parameters to define severity and progression of neurological diseases. The NFL and ganglion cell complex (GCC) thinning are strongly associated with MS, and with brain substructure volumes relevant to MS. Of note, these results were found in patients without optic neuritis, i.e., in persons who were asymptomatic with regard to their vision. In longitudinal studies, GCC thinning was noted to be significantly greater among patients with active MS than stable MS. A recently published longitudinal study also found an association between rates of atrophy of the GC and inner...
plexiform layer and global neurodegeneration, and more specifically rates of atrophy of the whole brain, white matter, gray matter, and thalamus. As a result, OCT is increasingly being used to gauge MS progression and has been used as an objective secondary measure in a clinical trial for relapsing/remitting MS.

**REVIEW RESULTS**

**Use of OCT in Detecting Damage to the RNFL and Other Retinal Structures in AD**

Most studies investigating OCT measures and cognition have focused on group comparisons of RNFL thickness in persons with significant cognitive loss (or diagnosis of AD) and persons with normal cognition. Several OCT studies have found decreased RNFL thickness in AD vs controls. Of these, a number of studies have found overall thinning (integrating data from all quadrants), while others have found a greater reduction in thickness of the inferior quadrant, or selective thinning of the superior quadrant. In addition to changes in RNFL thickness in AD, several studies have also reported on the presence of other retinal changes correlated with cognitive decline. Studies have detected a significant decrease in the combined RNFL and GC layer within the macular region and reduced mean total macular volume compared with healthy controls.

Studies examining OCT parameters in association with continuous measures of cognitive function have found conflicting results. Iseri et al found that total macular volume and Mini Mental Status Exam (MMSE) scores were significantly correlated in AD. The EPIC-Norfolk study also reported an association between RNFL thickness (measured by Heidelberg Retina Tomograph) and cognitive test scores assessing global function, recognition, learning, episodic memory, and premorbid intelligence in a population of older British adults. In contrast, others have found that OCT measurements were not correlated with MMSE, ADAS-Cognitive subscale, and Clinical Dementia Rating (CDR) evaluations. This lack of consensus in the association between OCT measurements and cognitive function may in part be due to the inconsistency in the types of cognitive function tests administered. Based on whether cognitive measurements assess global cognitive function or specific subdomains of cognition, associations with OCT measurements may vary.

In addition, there is also a lack of consensus on which retinal measurements (i.e., peripapillary RNFL, macular thickness, macular volume, etc.) are most likely to reflect AD. One study by Larrosa et al combined several of these OCT measurements to calculate and validate a linear discriminant function (LDF) for OCT and demonstrated decreased RNFL thickness in AD. Their LDF, which combined OCT measurements (circumpapillary RNFL thickness and retinal measurements), had better diagnostic ability compared with individual OCT parameters. The best parameter for distinguishing AD patients from healthy subjects was the Spectralis RNFL LDF. This demonstrated the capacity for using OCT as a potential diagnostic tool in AD and raises the question of which retinal measurements should be made in association with cognitive function.

**OCT Findings in Early Cognitive Impairment prior to AD**

If OCT is to be clinically useful, it will need to contribute to the identification of individuals likely to develop cognitive decline as a result of AD pathologic processes which are operative prior to dementia, i.e., persons with MCI due to AD, in whom treatment is most important. Indeed, several previous studies have investigated OCT measures in group comparisons of persons with MCI and healthy controls with normal cognitive function. Several studies have found that the overall RNFL thickness was significantly decreased in AD and MCI compared with healthy controls. However, data on regional selectivity of the RNFL in AD and MCI are varied. One study found a significant reduction in RNFL thickness in AD and MCI compared with controls in all four quadrants, while another study found a significant decrease in RNFL thickness in only the superior and inferior quadrants in AD and MCI. Kesler et al found a significant decrease in RNFL thickness in the inferior quadrants of patients with AD and MCI compared with controls. In addition, Shen et al found that in patients with MCI, inferior quadrant RNFL thickness was inversely associated with better cognitive function, reflected in higher episodic memory scores.

Other studies have compared additional retinal measures in AD patients, patients with MCI and controls; these measures include macular volume, choroidal thickness, and ganglion cell-inner plexiform layer (GC-IPL). One investigation showed decreased macular volume in AD and MCI compared with controls, though another found that MCI patients had a greater macular volume, followed by healthy controls, then AD patients. Bulut et al found significantly reduced choroidal thickness in AD and MCI in all investigated regions including subfoveal, temporal, and nasal regions, and Cheung et al found significantly reduced GC-IPL in AD and MCI. Thus, studies investigating changes in OCT measures have found RNFL thinning in MCI similar to that reported in AD, but regional selectivity and other retinal changes in MCI remain varied.
Studies investigating the association between OCT measures and continuous measures of cognition in the disparate groups of AD vs MCI vs controls have reported conflicting results. Some have found no correlation between MMSE scores and thickness of RNFL or macular volume. In contrast, others have found significant correlations between MMSE scores and RNFL thickness, as well as choroidal thickness at all locations. One study comparing RNFL thickness in AD vs LBD vs Parkinson’s disease dementia found that MMSE scores and CDR vs Parkison’s disease dementia found that MMSE scores and CDR vs LBD comparisons. Several of the aforementioned studies found that the RNFL in certain quadrants may be differentially affected in AD34,35,43,45; however, the rationale behind the preferential effects of a neurodegenerative brain disease on a specific region of the retina has yet to be established, raising the question of whether specific analyses of these regions reflect any prior hypothesis, or simply a chance finding generated by employment of multiple comparisons. The current method of comparison of NFL thickness maps to that of age-matched healthy controls in specific sectors presents with methodological challenges. Expected peaks do not necessarily coincide with peaks in thickness for every individual’s NFL map. Possible explanations for this phenomenon include the temporal peak shift in myopic individuals and the nasal peak shift in hyperopic individuals. In addition, if focal damage to the RNFL is indeed occurring in the context of Alzheimer’s, one potentially useful methodological approach may be to analyze the point of greatest difference between the expected and observed values in the ONH, customizing expected thickness at each point around the ONH with all available information. Thus, by using customized NFL thickness maps or other innovative approaches, investigators could focus on measuring changes in the most heavily affected area of the retina to investigate the potential focal effects of AD.

In addition to the possible focal effects of AD on the RNFL, it is also possible that only specific retinal cell types are affected in AD and other brain diseases. For example, research shows changes in specific retinal layers in different subtypes of spinocerebellar atrophy. In particular, the GCC-IP complex in the macula has been associated with AD. Based on the potential differential effects of AD on specific types of retinal cells, there are different OCT measures that could be used to identify and track AD. If AD-related damage is most strongly associated with GC damage within the macula, then macular GC-IPL thickness would serve as an appropriate measure of the retinal changes in AD. Conversely, if GCs throughout the retina are damaged in persons with AD, this may be best evaluated in measurements of the peripapillary retinal nerve layer, which reflects all axonal projections leaving the retina to join the optic nerve. Thus, further investigation into the association of AD and RNFL issues. First, all studies use clinical diagnosis of AD with no neuropathologic confirmation, making it more difficult to establish a valid association of neural OCT findings with AD. In addition, it is unclear whether AD damage to GCs and the RNFL is diffuse or focal. If damage is indeed focal, it remains unclear which regions may be more severely affected, and how this regionality is best established as fact as opposed to an artifact of multiple comparisons.
thinning is needed to determine the potential focal and cell-specific effects of AD.

In order to more effectively clarify this relationship between OCT measures and cognition, studies should also take into account variables that could potentially affect the association between cognition and OCT measures (particularly RNFL thickness). Intraocular pressure may affect the precision of association measures as it is a strong risk factor for glaucoma and its associated GC loss.53–56 Thus far, these variables have been inconsistently measured in clinical studies (Fig. 1). For example, IOP is only assessed in one study relating GCC or RNFL thickness to cognitive outcomes.38 In studies that have not accounted for IOP, differences in GC numbers may be due to the differential effects of IOP rather than a shared eye/brain process of neural damage. In addition, few studies have adjusted for axial length. In the presence of greater axial length, RNFL thickness measures may be incorrect due to magnification effects leading to an artifactual minification of the image.60–63 This would result in a smaller observed measurement of the RNFL. Increased axial length is also associated with more education and time spent reading during childhood,64 and this difference in educational background may strongly affect cognitive scores.65 Failure to adjust for axial length as a confounding variable may skew the association of RNFL thickness and cognitive outcomes, suggesting an association between decreased RNFL thickness and better cognitive function.57,58 Cognitive testing results may also be affected by visual defects (i.e., difficulty distinguishing the lines in the Trails test), which would be expected to accompany thinning of the RNFL, as opposed to true cognitive impairment. Thus, visual function may confound the association between OCT measurements and cognitive testing outcomes. Studies may account for this by conducting longitudinal studies and mediation analyses to estimate direct and indirect (mediated by vision) effects of OCT measures. This will yield estimates of decline in cognitive testing scores attributed to vision loss separate from estimates in decline due to degeneration of the RNFL. Studies may also utilize nonvisual cognitive assessments, so estimates of cognitive function are less impacted by visual deficits.

Other limitations in the current literature include failure to have OCT images read at an established reading center leading to the inclusion of artifacts (i.e., retinal layer missegmentation) which may have contributed to producing erroneous values41 and the variation in measurement differences in assessing cognitive and retinal changes. Due to the limited accuracy of the clinical diagnosis of dementia, OCT measures must be investigated in the setting of a proven etiology of cognitive impairment in order to assess its potential use as a diagnostic tool. Future studies may include the validation of RNFL thickness attenuation against known biomarkers of dementia or positron-emission tomography scans and pathology. Finally, the majority of previous studies were cross-sectional, making it difficult to establish temporality (Table 1). The observed retinal findings may have preceded cognitive changes, occurred simultaneously, or even occurred after pathologic changes in the brain due to dementia. This temporality is important to determine whether OCT can be used to aid in the early detection of dementia.

CONCLUSION

Despite the methodological challenges in assessing the use of OCT in dementia, this technology offers a potentially objective, noninvasive method of determining the etiology of cognitive decline, identifying persons with early-stage disease, and predicting which persons are at greater risk for future cognitive decline. Current research showing structural and physiological similarities between the retina and CNS, as well as more specific
retinal findings in AD, suggests a potential association between retinal changes and cognitive impairment due to AD or other cerebral neurodegenerative conditions. Thus, OCT measures may serve as a marker of the different pathogenic processes underlying cognitive impairment and dementia type. Further work is needed to determine whether structural OCT measures can specifically distinguish AD-related cognitive impairments to non-AD changes and whether OCT can predict individuals who are likely to go on to develop more rapid cognitive loss. Optical coherence tomography angiography should also be further investigated to determine whether it can be useful in identifying persons with specific types of dementia where vascular disease is relevant (i.e., VaD and possibly AD). Future methodologically robust research is needed to clarify the possible foci of retinal damage caused by cognitive impairment, and longitudinal studies accounting for potential confounders are needed to determine the temporality of the possible association between retinal changes and dementia.

CLINICAL SIGNIFICANCE
Implications

The use of OCT measurements as objective biomarkers of dementia type and rapid progression due to AD has several implications for both the fields of ophthalmology and neurology. First, it adds complexity to the monitoring of ocular diseases. There are several ocular conditions, such as glaucoma, in which a reduction in RNFL thickness is attributed to a glaucomatous process. There is also an expected reduction in the number of GCs with aging. However, the studies discussed above illustrate that other systemic factors add variability to the accepted normative level of GCL loss. Hence, in individuals with both ocular disease and systemic comorbidities, there may be an expected level of age-related GCL loss superimposed upon GCL loss caused by systemic factors and ocular diseases. The same complexity would apply for other neuro-ophthalmologic disease processes. Consideration must be given to the idea that other systemic processes may affect metrics which we have traditionally considered solely to reflect local disease processes. These implications make it increasingly difficult to quantify and accurately attribute changes in RNFL thickness to a glaucomatous process, neuro-ophthalmic condition, or a systemic neurocognitive disease.

The use of OCT to measure biomarkers in pathologic processes underlying dementia and cognitive decline also has implications in the practice of neurology. Optical coherence tomography measures may even be used as an objective noninvasive biomarker to follow progression of other neurologic diseases, such as MS. Future work will determine whether OCT measures may be useful in the field of cognition if the demonstrated retinal changes prove to be true in the context of cognitive impairment.

REFERENCES

1. Abbott A. Dementia: a problem for our age. Nature 2011 Jul;475(7355):52-54.
2. Snowden JS, Thompson JC, Stopford CL, Richardson AM, Gerhard A, Neary D, Mann DM. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011 Sep;134(Pt 9):2478-2492.
3. Robillard A. Clinical diagnosis of dementia. Alzheimer's Dement 2007 Oct;3(4):292-298.
4. Hunter CA, Kirson NY, Desai U, Cummings AKG, Faries DE, Birnbaum HG. Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries. Alzheimer's Dement 2015 Aug;11(8):887-895.
5. Qian W, Schweizer T, Munoz D, Fischer CE. Misdiagnosis of Alzheimer's disease: inconsistencies between clinical diagnosis and neuropathological confirmation. Alzheimer's Dement 2016 Jul;12(7):5293.
6. Koepsell TD, Gill DP, Chen B. Stability of clinical etiologic diagnosis in dementia and mild cognitive impairment. Am J Alzheimers Dis Other Demen 2013 Dec;28(8):750-758.
7. Gill DP, Hubbard RA, Koepsell TD, Borrie MJ, Petrella RJ, Knopman DS, Kukull WA. Differences in rate of functional decline across three dementia types. Alzheimer's Dement 2013 Oct;9(5 Suppl):S563-571.
8. Garcia-Ptacek S, Farahmand B, Kåreholt I, Religa D, Cuadrado ML, Erikssdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis 2014 Mar;41(2):467-477.
9. Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, O'Brien RJ, Selnes OA, Albert MS, BI0CARD Research Team. Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol 2016 Jun;73(6):698-705.
10. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011 May;7(3):28-292.
11. London A, Benhar I, Schwartz M. The retina as a window to the brain—from eye research to CNS disorders. Nat Rev Neurol 2013 Jan;9(1):44-53.
12. Ikram MK, Cheung CY, Wong TY, Chen CPLH. Retinal pathology as biomarker for cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2012 Sep;83(9):917-922.
13. Sivak JM. The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease. Invest Ophthalmol Vis Sci 2013 Jan;54(1):871-880.
14. Chang LYL, Lowe J, Ardiles A, Lim J, Grey AC, Robertson K, Danesh-Meyer H, Palacios AG, Acosta ML. Alzheimer's disease in the human eye. Clinical tests that identify ocular and visual information processing deficit as biomarkers. Alzheimers Dement 2014 Mar;10(2):251-261.
15. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011 Sep;1(1):a006189.
16. Karantzoulis S, Galvin JE. Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother 2011 Nov;11(11):1579-1591.
17. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, Frohman EM, Cutter G, Calabresi PA. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007 Oct;69(16):1603-1609.
18. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007 Dec;69(24): 2197-2204.
19. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci 2013 Apr;5:17.
20. Tsai CS, Ritch R, Schwartz B, Lee SS, Miller NR, Chi T, Hsieh FY. Optic nerve head and nerve fiber layer in Alzheimer’s disease. Arch Ophthalmol 1991 Feb;109(2):199-204.
21. Lesage SR, Mosley TH, Wong TY, Szklo M, Knopman D, Catvellier DJ, Cole SR, Klein R, Coresh J, Coker LH, et al. Retinal microvascular abnormalities and cognitive decline: the ARIC 14-year follow-up study. Neurology 2009 Sep;73(11):862-868.
22. Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ, Mosley TH, Klein BE, Hubbard LD, Szkle M. Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 2002 Jun;33(6):1487-1492.
23. Kawasaki R, Cheung N, Mosley T, Islam AF, Sharrett AR, Klein R, Coker LH, Knopman DS, Shibata DK, Catvellier D, et al. Retinal microvascular signs and 10-year risk of cerebral atrophy: the atherosclerosis risk in communities (ARIC) study. Stroke 2010 Aug;41(8):1826-1828.
24. Adhi M, Duker JS. Optical coherence tomography – current and future applications. Curr Opin Ophthalmol 2013 May;24(3):213-221.
25. Podoleanu AG. Optical coherence tomography. J Microsc 2012 Sep;247(3):209-219.
26. Saidha S, Sotirchos ES, Oh J, Syc SB, Seigo MA, Shiee N, Eckstein C, Durbin MK, Oakley JD, Meyer SA, et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurology 2013 Jan;70(1):34-43.
27. Ratchford JD, Saidha S, Sotirchos ES, Oh JA, Seigo MA, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Conger A, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013 Jan;80(1):47-54.
28. Saidha S, Al-Louzi O, Ratchford JD, Bhargava P, Oh J, Newsome SD, Prince JL, Pham D, Roy S, van Zijl P, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four-year study. Ann Neurol 2015 Nov;78(5):801-813.
29. Winges KM, Werner JS, Harvey DJ, Cello KE, Durbin MK, Baker LJ, Calabresi PA, Keltner JL. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. J Neuroophthalmology 2013 Dec;33(4):322-329.
30. Moschos M, Markopoulos I, Chatziralli I, Rouvas A, Papageorgiou SG, Ladas I, Vassilopoulos D. Structural and functional impairment of the retina and optic nerve in Alzheimer’s disease. Curr Alzheimer Res 2012 Sep;9(7): 782-788.
31. Marziani E, Pomati S, Ramolfo P, Cigada M, Giani A, Mariani C, Staurenghi G. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer’s disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2013 Sep;54(9):5953-5958.
32. Iseri PK, Altınaoğlu, Tokay T, Yüksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuropthalmol 2006 Mar;26(1):18-24.
33. Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, Ma D. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence in optical coherence tomography. Neurosci Lett 2010 Aug;480(1):69-72.
34. Shi Z, Wu Y, Wang M, Cao J, Feng W, Cheng Y, Li C, Shen Y. Greater attenuation of retinal nerve fiber layer thickness in Alzheimer’s disease patients. J Alzheimers Dis 2014;40(2): 277-283.
35. Kirbas S, Turkýılmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuropthalmol 2013 Mar;33(1):58-61.
36. Khawaja AP, Chan MPY, Yip JLY, Broadway DC, Garway-Heath DF, Luben R, Hayat S, Matthews FE, Brayne C, Khaw KT, et al. Retinal nerve fiber layer measures and cognitive function in the EPIC-Norfolk cohort study. Invest Ophthalmol Vis Sci 2016 Apr;57(4):1921-1926.
37. Gharbiiya M, Trebbastoni A, Parisi F, Mangiannello, Cruciani F, D’Antonio F, De Vico U, Imbriano L, Campanelli A, De Lena C. Choroidal thinning as a new finding in Alzheimer’s Disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimers Dis 2014 Feb;40(4):907-917.
38. Larrosa JM, Garcia-Martin E, Bambo MP, Pinilla J, Polo V, Otin S, Satue M, Herrero R, Pablo LE. Potential new diagnostic tool for Alzheimer’s disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci 2014 May;55(5):3043-3051.
39. Oktem EO, Derle E, Kibaroglu S, Oktem C, Akkoynu I, Can U. The relationship between the degree of cognitive impairment and retinal nerve fiber layer thickness. Neurol Sci 2015 Jul;36(7):1141-1146.
40. Ho XF, Liu YT, Peng C, Zhang F, Zhuang S, Zhang JS. Optical coherence tomography assessed retinal nerve fiber layer thickness in patients with Alzheimer’s disease: a meta-analysis. Int J Ophthalmol 2012 Jun;5(3):401-405.
41. Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr 2015 Jan-Feb;60(1):162-167.
42. Cheung CY, Ong YT, Hilal S, Ikram MK, Low S, Ong YL, Venkatasubramanian N, Yap P, Seow D, Chen CL, et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 2015;45(1):45-56.
43. Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin Neurophysiol 2011 Nov;122(11):1712-1722.
44. Ascaso FJ, Cruz N, Modrego PJ, Lopez-Anton R, Santabárbara J, Pascual LF, Lobo A, Cristóbal JA. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J Neurool 2014 Aug;261(8): 1522-1530.
45. Liu D, Zhang L, Li Z, Zhang X, Wu Y, Yang H, Min B, Zhang X, Ma D, Lu Y. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurol 2015 Feb;15:14.

46. Shen Y, Liu L, Cheng Y, Feng W, Shi Z, Zhu Y, Wu W, Li C. Retinal nerve fiber layer thickness is associated with episodic memory deficit in mild cognitive impairment patients. Curr Alzheimer Res 2014 Mar;11(3):259-266.

47. Bulut M, Yaman A, Erol MK, Kurtuluş F, Toslak D, Doğan B, Çoban DT, Başar EK. Choroidal thickness in patients with mild cognitive impairment and Alzheimer’s type dementia. J Ophthalmol 2016;2016:7291257.

48. Moreno-Ramos T, Benito-León J, Villarejo A, Bermejo-Pareja F. Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease. J Alzheimers Dis 2013;34(3):659-664.

49. Shen Y, Shi Z, Jia R, Zhu Y, Cheng Y, Feng W, Li C. The attenuation of retinal nerve fiber layer thickness and cognitive deterioration. Front Cell Neurosci 2013 Sep;7:142.

50. Lebranchu P, Le Meur G, Magot A, David A, Verny C, Shen Y, Liu L, Cheng Y, Feng W, Shi Z, Zhu Y, Wu W, Li C. The attenuated detection and thickness reproducibility with spectral-domain-optical coherence tomography in glaucoma. Invest Ophthalmol Vis Sci 2013 Sep;54(9):5076-5083.

51. Michalik A, Martin J-J, Van Broeckhoven C. Spinocerebellar ataxia type 1. J Neuropathol 2013 Sep;72(9):894-909.

52. Mwanza J-C, Oakley JD, Chang RT, Knight OJ, Weber M, Milea D. Maculopathy and spinocerebellar ataxia type 1. J Neuroophthalmol 2013 Sep;33(3):225-231.

53. Feuer WJ. Macular ganglion cell-inner plexiform layer: automated detection and thickness reproducibility with spectral-domain-optical coherence tomography in glaucoma. Invest Ophthalmol Vis Sci 2011 Oct;52(11):8323-8329.

54. Alonso A, Bandeen-Roche K, Coker LH, Coresh J, Couper DJ, Griswold ME, et al. Impact of differential attrition on the association of education with cognitive change over 20 years of follow-up: the ARIC neurocognitive study. Am J Epidemiol 2014 Apr;179(8):956-966.

55. Harwerth RS, Wheat JL, Rangaswamy NV. Age-related losses of retinal ganglion cells and axons. Invest Ophthalmol Vis Sci 2008 Oct;49(10):4437-4443.

56. Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H, Keser N, Young KL, Harmel J, Hartung HP, Martin R, et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomodraphy. Mult Scler Int 2012 May;2012:1-10.

57. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 2012 Jun;135(Pt 6):1786-1793.